Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib


Keizman D., Sarid D., Lee J. L. , Sella A., Gottfried M., Hammers H., et al.

ONCOLOGIST, cilt.21, ss.1212-1217, 2016 (SCI İndekslerine Giren Dergi)

Özet

Background. Sunitinib is a standard treatment for metastatic clear cell renal cell carcinoma (mccRCC). Data on its activity in the rare variant of metastatic chromophobe renal cell carcinoma (mchRCC), are limited. We aimed to analyze the activity of sunitinib in a relatively large and homogenous international cohort of mchRCC patients in terms of outcome and comparison with mccRCC.